Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that therapies such as Eli Lilly/ICOS's Cialis (tadalafil) have improved side-effect profiles over existing drugs and will gain market share owing to their increased use in combination therapy to treat benign prostatic hyperplasia.

The new Pharmacor report, entitled Benign Prostatic Hyperplasia, finds that the most pressing unmet need in this market is for therapies with improved side-effect profiles. The report finds that physicians and urologists are increasingly prescribing both an alpha blocker and a 5-alpha-reductase inhibitor for patients who exhibit lower urinary tract symptoms and an enlarged prostate. This trend of using combination therapy, or polypharmacy, will continue as other drug classes enter the market.

"This market is characterized by a large patient population and significant commercial potential for companies that can deliver combination therapy products that address key medical needs including improvements in safety and symptom relief," said Vickie Lew, analyst at Decision Resources, Inc. "Future novel therapies with mechanisms of action that are distinct from those of current drugs will improve on the side-effect profiles of existing treatments."

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate gland that occurs as part of the aging process in most men. This condition is a major cause of lower urinary tract symptoms associated with urinary voiding dysfunction in men aged 50 or older.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Launch of New Drugs From Bayer and Boehringer Ingelheim will Generate Robust Growth in the Anticoagulant Market

View Now